U.S. Markets closed

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
28.85+0.09 (+0.31%)
At close: 4:04PM EDT
People also watch
MDTSTJBAXBCRBDX

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752
United States
508-683-4000
http://www.bostonscientific.com

SectorHealthcare
IndustryMedical Appliances & Equipment
Full Time Employees27,000

Key Executives

NameTitlePayExercisedAge
Mr. Michael F. MahoneyChairman, Chief Exec. Officer and Pres3.5MN/A52
Mr. Daniel J. BrennanChief Financial Officer and Exec. VP1.06M824.61k51
Mr. Timothy A. PrattChief Admin. Officer, Exec. VP, Gen. Counsel and Sec.1.33M1.36M67
Mr. Joseph M. FitzgeraldExec. VP and Pres of Rhythm Management886.99kN/A53
Mr. Kevin J. BallingerExec. VP and Pres of Interventional Cardiology997.76k2.79M44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Boston Scientific Corporation’s ISS Governance QualityScore as of September 1, 2017 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.